Analyzing CDT Equity (NASDAQ:CDT) & Reviva Pharmaceuticals (NASDAQ:RVPH)

CDT Equity (NASDAQ:CDT) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.

Valuation and Earnings

This table compares CDT Equity and Reviva Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22 million	($66,338.55)	0.00
Reviva Pharmaceuticals	N/A	N/A	-$19.86 million	($4.06)	-0.15

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

CDT Equity has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CDT Equity and Reviva Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1	0	0	0	1.00
Reviva Pharmaceuticals	1	2	5	0	2.50

Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 10,828.96%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than CDT Equity.

Profitability

This table compares CDT Equity and Reviva Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Institutional & Insider Ownership

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 10.8% of CDT Equity shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Reviva Pharmaceuticals beats CDT Equity on 8 of the 11 factors compared between the two stocks.

About CDT Equity

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.